Back to top
more

Chemours (CC)

(Delayed Data from NYSE)

$19.79 USD

19.79
1,636,123

-0.66 (-3.23%)

Updated Nov 8, 2024 04:00 PM ET

After-Market: $19.80 +0.01 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 13% (219 out of 251)

Industry: Chemical - Diversified

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Chemours (CC) Surpasses Q1 Earnings Estimates

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of 58.06% and 0.87%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Methanex (MEOH) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Methanex (MEOH) delivered earnings and revenue surprises of 20.65% and 6.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Northern Technologies (NTIC) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Northern Technologies (NTIC) delivered earnings and revenue surprises of -44.44% and 10.44%, respectively, for the quarter ended February 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold Onto Chemours (CC) Stock for Now

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand and its pricing actions.

Chemours (CC) Posts Break-Even Q4 Earnings, Sales Miss

by Zacks Equity Research

Chemours (CC) gains from increased prices across its segments amid headwinds from higher input cost inflation, adverse currency movements and soft demand in Europe & Asia in Q4.

Chemours (CC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

While the top- and bottom-line numbers for Chemours (CC) give a sense of how the business performed in the quarter ended December 2022, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Chemours (CC) Reports Break-Even Earnings for Q4

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of -100% and 5.93%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

FMC (FMC) Surpasses Q4 Earnings and Revenue Estimates

by Zacks Equity Research

FMC (FMC) delivered earnings and revenue surprises of 2.16% and 7.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Chemours (CC) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Implied Volatility Surging for Chemours (CC) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.

Albemarle (ALB) Up 0.3% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Albemarle (ALB) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Chemours (CC) Gains on Opteon Demand Amid Input Cost Woes

by Zacks Equity Research

While Chemours (CC) is exposed to headwinds from higher raw material costs, it gains on healthy Opteon demand, strong execution and its cost-reduction and pricing actions.

Chemours (CC) Earnings and Revenues Top Estimates in Q3

by Zacks Equity Research

Higher prices contribute favorably to Chemours' (CC) top line growth in the third quarter.

New Strong Sell Stocks for October 26th

by Zacks Equity Research

HES, JRVR and CC have been added to the Zacks Rank #5 (Strong Sell) List on October 26, 2022.

Chemours (CC) Surpasses Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Chemours (CC) delivered earnings and revenue surprises of 6.90% and 0.31%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Chemours (CC) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Chemours (CC) closed at $28.77 in the latest trading session, marking a -1.34% move from the prior day.

Earnings Preview: Methanex (MEOH) Q3 Earnings Expected to Decline

by Zacks Equity Research

Methanex (MEOH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemours (CC) to Post Q3 Earnings: What's in the Offing?

by Zacks Equity Research

While Chemours (CC) is likely to have benefited from healthy demand and pricing actions, raw material inflation and ore logistics constraints are expected to have affected its performance.

Earnings Preview: Chemours (CC) Q3 Earnings Expected to Decline

by Zacks Equity Research

Chemours (CC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Chemours (CC) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

Chemours (CC) closed the most recent trading day at $26.53, moving -1.38% from the previous trading session.

Chemours (CC) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Chemours (CC) closed the most recent trading day at $24.50, moving +1.66% from the previous trading session.

Are Options Traders Betting on a Big Move in Chemours (CC) Stock?

by Zacks Equity Research

Investors need to pay close attention to Chemours (CC) stock based on the movements in the options market lately.

Chemours (CC) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Chemours (CC) closed the most recent trading day at $24.10, moving +0.67% from the previous trading session.

Here's Why You Should Hold Onto Chemours (CC) Stock for Now

by Zacks Equity Research

While Chemours (CC) is exposed to supply-chain issues and higher input costs, it gains on healthy demand, strong execution and its cost-reduction and pricing actions.

Why This 1 Value Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.